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The proinﬂammatory activity of T helper 17 (Th17) cells can be beneﬁcial to the host during infection. However, uncontrolled or
inappropriate Th17 activation has been linked to several autoimmune and autoinﬂammatory pathologies. Indeed, preclinical and
clinical data show that Th17 cells are associated with several autoimmune diseases such as arthritis, multiple sclerosis, psoriasis,
and lupus. Furthermore, targeting the interleukin-17 (IL-17) pathway has attenuated disease severity in preclinical models of
autoimmune diseases. Interestingly, a recent report brings to light a potential role for Th17 cells in the autoinﬂammatory disorder
adult-onset Still’s disease (AOSD). Whether Th17 cells are the cause or are directly involved in AOSD remains to be shown. In this
paper, we discuss the biology of Th17 cells, their role in autoimmune disease development, and in AOSD in particular, as well as
the growing interest of the pharmaceutical industry in their use as therapeutic targets.
1. Th17 Cell Differentiation
Th17 cells are a novel class of helper CD4+ T cells described
in 2005 that secrete IL-17A, IL-17F, IL-21, and IL-22 [1–3].
Diﬀerentiation of na¨ ıve T cells towards a Th17 phenotype
is supported by several cytokines including transforming
growth factor-β (TGF-β), IL-1β, IL-6, IL-21, and IL-23
in mice and humans [4–8]. Indeed, ligation of toll-like
receptors TLR3, TLR4, or TLR9 induces secretion of TGF-β
and IL-6 that subsequently supports de novo diﬀerentiation
of na¨ ıve CD4+ T cells to Th17, cells in vitro [9]. Further, it
has been shown that TGFβ is required for the initiation of
Th17dependentautoimmuneencephalitisinvivo[10].TGF-
β prevents Th1 and Th2 diﬀerentiation by suppressing Stat4
and GATA-3 expression, thus allowing Th17 diﬀerentiation;
however, Th17 development also occurs in the absence of
TGF-β signaling [11, 12]. In an elegant study, Ivanov et al.
demonstrated that TGFβ and IL-6 promote IL-21R and IL-
23R expression by a mechanism implicating RORγT[ 13].
Moreover,IL-21expressionbyTh17cellsactsinanautocrine
manner to promote Th17 diﬀerentiation [14, 15], while
increased expression of IL-23R expression downstream of T-
cell activation and Th17 development allows IL-23 signaling
to further maintain Th17 activity in a Stat3-dependent
manner [4, 16]. Furthermore, IL-18 synergizes with IL-23
to promote IL-17 production by IL-23-primed CD4+ Tc e l l s
[17]. IL-18 was also shown to induce the ex vivo release of
IL-17 and IL-23 from lymphocytes of systemic lupus erythe-
matosus (SLE) patients [18]. It is well established that IL-18
isanimportantcytokineimplicatedinpromotingTh1polar-
ization, which is characterized by interferon (IFN-γ) release.
IFN-γ secretion subsequently activates both neutrophils and
macrophages, resulting in the intracellular killing of bacteria
and fungi [19]. In contrast, IL-1β negatively regulates Th1
diﬀerentiation by inducing cyclooxygenase (COX)-2, which
subsequently increases the secretion of prostaglandin E2
(PGE2)thatsuppressesIFN-γ production[20]thusallowing
Th17 diﬀerentiation. Indeed, IL-1β has been shown to
enhanceTh17responsesinthepresenceofIL-23[4,7].While
further investigation is needed to better understand the
biology of Th17 diﬀerentiation and the parameters involved
in this process, overall the above studies shed light and reveal
the complexity of this pathway (summarized in Figure 1).
2. IL-17: Expressionand Function
IL-17 is a potent proinﬂammatory cytokine that ampliﬁes
ongoing inﬂammation by inducing expression of tumor2 International Journal of Inﬂammation
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Figure 1: Implications of Th17 diﬀerentiation in the development of the immune response.
necrosis factor-α (TNF-α), IL-1β, and IL-6 in epithelial
a n de n d o t h e l i a lc e l l sa sw e l la so t h e rc e l lt y p e ss u c ha s
keratinocytes, synoviocytes, ﬁbroblasts, and macrophages.
IL-17, also known as IL-17A, is the founding member of
the structurally related IL-17 family, which includes IL-
17B, IL-17C, IL-17D, IL-17E (also called IL-25), and IL-
17F. IL-17F shares the highest amino acid identity with IL-
17A [21]. The IL-17 receptor family also has ﬁve members
withconservedextracellularﬁbronectinIII-likedomainsand
cytoplasmic “similar expression to FGF/IL-17R” (SEFIR)
domains [22]. IL-17 receptor expression proﬁles show that
IL-17RA and IL-17RC are present in diﬀerent cell types and
tissues.ImmunecellsmostlyexpressIL-17RA,whileIL-17RC
is found on the surface of epithelial cells and ﬁbroblasts [23,
24]. Upon engagement, IL-17R signaling activates NF-κB,
MAPK, and C/EBP pathways via SEFIR domain containing
the adaptor protein Act1. Act1 further interacts with TRAF6
and TAK1 to promote signal transduction and cytokine
and chemokine secretion [25]. Indeed, IL-17 stimulates
production of chemokines such as CXCL1, CXCL5, IL-8,
CCL2, and CCL7 that are responsible for recruitment of
neutrophils to the site of inﬂammation [26]. For example,
local production of IL-17 by Th17+ cells in the central
nervous system (CNS) promotes neutrophil recruitment in
a mouse model of multiple sclerosis (MS), experimental
autoimmune encephalomyelitis (EAE) [3, 10]. Furthermore,
IL-17 enhances granulopoiesis by triggering expression of G-
CSF and GM-CSF [27–29]. Although GM-CSF expression
is not required for Th17 diﬀerentiation, a recent study
showed that this cytokine is required for autoimmune
neuroinﬂammation via myeloid cells (CD45hi, CD11b+)
inﬁltrating the central nervous system during the eﬀector
phase of the response [30, 31].
3. Th17 Cellsand MicrobialImmunity
Th17 cells play an important role in host defense against
bacterial and fungal infection, especially at mucosal surfaces.
Production of IL-17 and IL-22 upon Th17 cell triggering
improves mucosal barrier surfaces by stimulating release of
antimicrobial peptides and recruiting neutrophils. However,
in viral and parasitic infections, Th17 responses can be detri-
mental to the host. During Theiler’s murine encephalomyeli-
tis virus (TMEV) infection, anti-IL-17 treatment inhibits
viral persistence and development of demyelinating disease
[32]. Further, it was demonstrated in this study that in vitro
treatment of bone marrow (BM) cells or astrocytes with
recombinant IL-17 increases expression of antiapoptotic
molecules Bcl-xl and Bcl-2, thus preventing destruction by
cytotoxic T cells. This results in persistence of the infection
by enhancing the survival of virus-infected cells. In addition,
it has been shown that pretreatment of target cells (coated
with viral peptide) with IL-17 reduced their susceptibility to
cytolytic killing by CD8+ T cells. In contrast, pretreatment
of CD8+ Tc e l l sd o e sn o ta ﬀect cytotoxicity. These results
indicate that IL-17 alters the susceptibility of the target cell
to apoptosis rather than the eﬀector T cell’s ability to kill
infectedcells.In vivo experimentsusingTMEV-infectedmice
treated with anti-IL-17 antibody showed that IL-17 blockade
enhances viral load and reduces expression of prosurvivalInternational Journal of Inﬂammation 3
Table 1: Preclinical mouse models showing a role for Th17 cells and the IL-17 pathway in autoimmunity.
Disease Model Role of Th17 Reference
Rheumatoid arthritis
Collagen-induced arthritis (CIA)
IL-23 (p19 subunit) KO mice have less Th17 cells and reduced
disease severity [35]
Collagen-induced arthritis (CIA) IL-17A KO mice have reduced disease incidence and severity [36]
IL-6R subunit gp130 (Y759F)
mutation
Enforced IL-6 expression enhances disease progression in an
IL-17A-dependent manner [37]
SKG-dominant active ZAP70 mutant IL-17A KO mice are resistant to arthritis [39]
HTLV-I Tg mice IL-17A KO mice are resistant to arthritis [41]
Inﬂammatory Bowel
disease
Adoptive transfer of CD4+CD45RBhi
cells to lymphopenic mice
IL-17A KO CD4+ T cells accelerated T-cell-mediated intestinal
damage [42]
Adoptive transfer of CD4+CD45RBhi
cells to lymphopenic mice
IL-17A, IL-17F, or IL-22 KO T-cells-induced colitis equally
compared to WT [43]
Dextran sodium sulfate (DSS)
IL-17F KO or IL-17A KO or mice treated with an anti-IL-17A
antibody showed severe weight loss and colonic epithelial
damage
[44, 45]
Dextran sodium sulfate (DSS) IL-17A KO showed substantially reduced colitis based on both
clinical score and mortality [46]
Psoriasis
Topical application of imiquimod
(IMQ)
Dermatitis is blocked in IL-23R KO and IL-17R KO mice [53]
IL-23 injection IL-6-dependent accumulation of Th17 cells in psoriatic skin,
dermatitis was greatly reduced in IL-22 KO or IL-17A KO mice [55, 56]
K5.Stat3C transgenic mice
Constitutively express activated Stat3 within keratinocytes
promotes Th17 cells, and anti-IL-23 was shown to block
epidermal hyperplasia; however, anti-IL-17 had only partial
eﬀect
[57]
Type 1 diabetes
RIP-OVA mice (mice expressing OVA
peptide in pancreatic beta islet cells )
IL-17 producing CD8+ T cells (Tc17) cause diabetes in an
IL-17A- and IL-17F-dependent manner when adoptively
transferred to RIP-OVA mice
[59]
Nonobese diabetes (NOD)
Anti-IL-17A antibodies inhibit diabetes during the eﬀector
phase of disease (at 10 weeks of age) but not during the
initiation of disease (mice less than 5 weeks of age)
[60]
Bcl-xl and Bcl-2 proteins in both inﬁltrating macrophages
and resident microglia. This antibody treatment signiﬁcantly
increases the elimination of newly introduced viral epitope
peptide-loaded target cells. Altogether, these ﬁndings suggest
that IL-17 expression promotes viral persistence by inhibit-
ing apoptosis of virally infected cells.
Moreover, in parasitic infection, IL-27R-deﬁcient mice
infected with Toxoplasma gondii develop severe neuroin-
ﬂammation that is characterized by prominent IL-17 re-
sponse [33]. When infected with Leishmania major, mice
lacking IL-27R develop more severe lesions that are associ-
ated with the presence of IL-17+ CD4+ cells [34]. Overall,
these experiments suggest that the inappropriate develop-
ment of Th17 cells in some infections could lead to increased
disease progression and chronic infection rather than remis-
sion and microbe clearance.
4. Th17 CellsinPreclinicalModels
of Autoimmunity
4.1. Rheumatoid Arthritis (RA). Several mouse models exist
for studying the mechanism of RA development. In these
models, genetic inactivation of IL-17A or IL-17F has shown
that Th17 cells do play a role in disease progression (summa-
rized in Table 1).
In the collagen-induced arthritis (CIA) model, injection
of type II collagen (CII) together with Complete Freud’s
adjuvant (CFA) containing heat-killed Mycobacterium tuber-
culosis triggers cell-mediated and humoral responses char-
acterized by cellular inﬁltration and synovitis of the joints,
resulting in swelling of the paws and progressive destruction
of bone and cartilage. Disease is detected by measuring CII-
speciﬁc antibody levels in the serum. It has been shown
that mice deﬁcient in IL-23 (p19 subunit) show reduced4 International Journal of Inﬂammation
numbers of IL-17+ cells in the draining lymph nodes and
havelessseverediseasethanmicelackingIL-12(p35subunit)
[35]. In the same model, disease incidence and severity are
greatly attenuated in IL-17A KO mice [36]. Further, IL-
17A and IL-17F double KO mice do not show additional
disease suppression, indicating that IL-17F does not have
any additive or synergistic eﬀect [23]. These data suggest
that IL-23-dependent Th17 function and production of IL-
17 support arthritis disease development.
Mice with a mutation in the gp130 subunit of IL-6R
(Y759F) have disrupted SOCS3-mediated negative feedback
and develop spontaneous arthritis as assessed by degree of
swelling in the joints. In this model, increased IL-6 expres-
sion via hydrodynamics-based transfection enhances disease
progression in an IL-17A-dependent manner [37]. IL-17A-
deﬁcient mice were resistant to arthritis while elevated IL-17
expression induced arthritis. Interestingly, IL-6 was required
for IL-17A-induced arthritis, in Y759F mutants. These ﬁnd-
ings suggest that a positive feedback loop of IL-6 and IL-17
secretion is active in arthritis.
Mice with an activating mutation in the SH2 domain of
ZAP-70, a key signal transduction molecule in T cells, spon-
taneously develop T-cell-mediated chronic autoimmune
arthritis [38].Theseso-calledSKGmicedevelop autoreactive
T cells due to defective negative selection in the thymus. In
this model, arthritis is suppressed in the absence of IL-17A
[39], suggesting that the pathogenic T cells are indeed Th17+
cells.
Further, transgenic mice carrying the human T-cell
leukemia virus type I (HTLV-1) tax gene with its own LTR
promoter (HTLV-I Tg mice) develop chronic inﬂammatory
polyarthropathy that resembles RA in humans [40]. This
model is dependent on IL-1α/β and IL-6 and was recently
shown to be dependent on IL-17A, as IL-17A KO mice are
resistant to arthritis [41].
4.2. Inﬂammatory Bowel Disease and Crohn’s Disease. The
roles of Th17 cells in inﬂammatory bowel disease (IBD) and
Crohn’s Disease (CD) are somewhat more controversial than
in other autoimmune diseases. Th17 cells were studied in a
model for IBD, where na¨ ıve CD4+CD45RBhi cells adoptively
transferred to lymphopenic mice cause colitis characterized
by weight loss, diarrhea, and histological analysis (degree
of epithelial hyperplasia and goblet cell depletion, leukocyte
inﬁltration in the lamina propria, area of tissue aﬀected,
crypt abscesses, submucosal inﬂammation, and ulcers).
Indeed, IL-17A KO CD4+ T cells accelerated T-cell-mediated
intestinal damage compared to wild-type (WT) CD4+ Tc e l l s
[42]. IL-17A KO T cells displayed increased IFNγ produc-
tion, suggesting that IL-17A can downregulate Th1 response
and potentially protect against Th1-mediated tissue damage.
However, this ﬁnding is controversial as another group using
the same model showed that IL-17A, IL-17F, or IL-22 KO T
cells induced colitis equally compared to WT T cells [43].
Treatment of mice upon adoptive transfer of IL-17F KO T
cells with a neutralizing anti-IL-17A antibody signiﬁcantly
suppressed disease, indicating that IL-17A and IL-17F have
redundant biological eﬀects.
Additional models of IBD used to investigate the role
of Th17 cells give mixed results as well. In the dextran-
sodium-sulfate- (DSS-) induced colitis model, in which
diseaseprogressionisprimarilyduetoincreasedneutrophilic
inﬁltration of the inﬂamed tissue, mice lacking IL-17F
or IL-17A or mice treated with an anti-IL-17A antibody
show severe weight loss and colonic epithelial damage [44,
45]. Conversely, a diﬀerent study reported that genetic
inactivation of IL-17A substantially reduces colitis based on
both clinical score and mortality compared to WT animals,
suggesting that IL-17 promotes colitis [46]. In this study,
G-CSF and MCP-1 are reduced in DSS-treated IL-17A KO
mice compared to treated WT mice. The disparities in these
s t u d i e sm a yb ed u et od i ﬀerent intestinal microbial ﬂora that
aﬀects the immune response in this disease model. Interest-
ingly, IL-22 expression by CD4+ T cells and NK cells also has
a protective role in both the DSS and T cell transfer models,
as transfer of T cells from IL-22-deﬁcient mice worsens dis-
ease [47].
It has recently been shown that during intestinal inﬂam-
mation induced by anti-CD3 treatment, pathogenic Th17
cells in the gut express IL-10 receptor (IL-10R) and are
negatively regulated by Foxp3− and Foxp3+ T r e g si na nI L -
10-dependentmanner[48].IL-10Rexpressionisrequiredfor
Tregs to maintain suﬃcient IL-10 production and mediate
inhibition of Th17 cells [49]. Paradoxically, Treg depletion
in Foxp3-DTR mice may result in a reduced frequency of
antigen-speciﬁc IL-17 producers in draining lymph nodes
and blood and is correlated with reduced inﬂammatory skin
responses during Candida albicans infection. This is likely
mediated by a regulation of IL-2 availability [50, 51].
4.3. Psoriasis. IL-17+ T cells are increased in the dermis of
psoriatic skin lesions [52]. In mice, topical application of
imiquimod (IMQ), a TLR7/8 ligand, induces psoriasis-like
dermatitis characterized by increased epidermal cell prolifer-
ation, neutrophil accumulation, and CD4+ T cell inﬁltration
[53]. In this model, IMQ induces IL-23, IL-17A, and IL-
17E expression in the epidermis and increased Th17 cells
in the spleen. Furthermore, dermatitis is almost completely
blocked in mice deﬁcient in IL-23R and IL-17R. Psoriasis-
like epidermal hyperplasia can be induced in the ears of mice
by directly injecting IL-23 [54] and was shown to be IL-6
dependent [55]. In IL-23 induced psoriasis, CCR6+Th17+
cells accumulate in psoriatic skin where CCL20 (the CCR6
ligand) expression is abundant. Comparison of CCR6 KO
and WT mice conﬁrmed that CCR6 expression was required
for IL-23-induced dermatitis. IL-22 and IL-17A are also
necessary for epidermal hyperplasia in this model, as der-
matitis was greatly reduced in IL-22 KO or IL-17A KO
mice [56]. Further, K5.Stat3C transgenic mice constitutively
express activated Stat3 within keratinocytes and develop
skin lesions with histological and cytokine proﬁles similar
to those seen in human psoriasis [57]. In this model, anti-
IL-23 antibody treatment blocks epidermal hyperplasia and
lowers transcript levels of Th17 cytokines (IL-17 and IL-
22), β-defensins, and S100A. However, blocking IL-17 with
anti-IL-17 antibodies or using genetic inactivation models
only moderately reduced psoriasis. Overall, these ﬁndingsInternational Journal of Inﬂammation 5
show that IL-23-mediated induction of IL-17 secretion and
Th17+ recruitment in the inﬂamed tissue eﬃciently promote
dermatitis; however, IL-17 itself is only partially required.
Interestingly, in this model, the T-cell-independent psoriatic
dermatitis that spontaneously develops in IL-1RN KO mice
is not aﬀected by IL-17A deﬁciency [58].
4.4. Type 1 Diabetes (T1D). In vitro activated OT1 T cells,
transgenic CD8+ T cells that express the alpha and beta T-
cell-receptor speciﬁc for OVA peptide, induce rapid diabetes
onset when transferred to mice expressing OVA peptide in
pancreatic beta islet cells (RIP-OVA mice). It has been shown
thatinvitrotreatmentofOT1cellswithIL-23promotestheir
diﬀerentiationintoIL-17producingCD8+ Tcells(Tc17)and
causes diabetes in an IL-17A- and IL-17F-dependent manner
when adoptively transferred to RIP-OVA mice [59]. In a
diﬀerent setting, using the nonobese diabetes (NOD) animal
model for Type 1 diabetes, disease is inhibited following
treatment with anti-IL-17A antibodies during the eﬀector
phase of disease (at 10 weeks of age) rather than during the
initiation of disease (mice less than 5 weeks of age) [60]. In
contrast, it has been shown that IL-17A KO on the NOD
background have comparable incidence of hyperglycemia to
NOD mice with a WT allele for IL-17A. This could be due to
expressionofotherIL-17familymemberssuchIL-17F.Thus,
while Th17 cells and IL-17A seem to play a role in T1D, the
precise mechanism is not yet completely understood.
5. Th17 Links Autoimmunitywith Host Defense
While it is clear that uncontrolled inﬂammation causes
autoimmune pathologies, it remains to be seen what triggers
the inﬂammation in these diseases. Several new studies sug-
gest that exposure to pathogens initiates immune responses
with an autoinﬂammatory outcome. Indeed, Th17 cells are
induced by commensal bacteria in the small intestine lamina
propria and are dependent on TGFβ but independent of
IL-21, IL-23, and TLR signaling (MyD88 and Trif) [61].
However, the link between Th17 cells in the gut and au-
toimmune disease development at peripheral sites is not
shown.
K/BxN transgenic mice express autoreactive T cells
speciﬁc for glucose 6 phosphate isomerase that promotes
generation of high levels of auto-reactive antibodies, which
subsequently induces ankle thickening. When these mice
are housed in germ-free (GF) conditions, arthritis is greatly
attenuated [62]. Indeed, disease reduction is correlated with
a decreased number of T follicular helper cells and germinal
center B cells in GF mice, suggesting that lack of microbes
and their eﬀect in adaptive immune response accounts for
the reduced arthritis. Further, analysis of helper T cells from
K/BxN mice in GF conditions compared to animals housed
in speciﬁc pathogen-free (SPF) facility shows a signiﬁcant
reduction in Th17 gene signatures (IL-17A, IL-21, IL-22,
RORγT, and CCR6). Neutralization of IL-17 with blocking
antibodies at the time of arthritis onset (25 days old mice)
completely abrogates disease, which is reﬂected in the low
serum autoantibody titers. Moreover, following adoptive
transfer, B cells from IL-17R-deﬁcient mice failed to partake
in the germinal center development. Overall, this study re-
veals a potential role of the IL17 pathway in regulating B
cell function that a lack of Th17 cells and their downstream
eﬀects on germinal center B cells are critical factors in the
disease reduction. A diﬀerent study using IL-1R-antagonist-
(IL-1RN-) deﬁcient mice that spontaneously develop T-cell-
mediated arthritis further supports a contribution of Th17
cells in autoimmune progression. Indeed, IL-1RN KO mice
housed in germ-free conditions display reduced arthritis
assayed by ankle thickness and histopathological analysis,
while arthritis can be induced by infection with Lactobacillus
biﬁdus in a TLR4-dependent manner [63]. Disease remission
is associated with reduced Th17 cell number and decreased
IL-17 secretion. In support of the above ﬁndings, mice in the
SKG model (described above) do not develop arthritis if the
animalsarehousedinmicrobiallycleanenvironment,despite
the presence of arthritogenic autoimmune T cells, [64].
TreatingmicewiththeyeastTLR2ligandzymosanorglucose
polymerβ-1,3-D-glucans(β-glucans),themainconstituents
of zymosan, induces severe arthritis in SKG mice. Blockade
of Dectin-1, a major β-glucan receptor, is able to prevent
SKG arthritis triggered by β-glucans. Finally, polyinosinic-
polycytidylic acid (poly[I:C]), a double-stranded RNA, also
showed a mild arthritogenic eﬀect in SKG mice. Together
these studies strongly support the existence of a link between
microbialstimuliandinnatesignalingtoTh17activationand
autoimmunity (summarized in Figure 2).
6.PotentialSmallMolecules toTarget
Th17 Cells
Recent studies have identiﬁed small molecules that may be
usedastherapeuticstotargetTh17+ cells.Thesmallmolecule
Halofuginone selectively inhibits mouse and human Th17
diﬀerentiation by activating the amino acid starvation re-
sponse (AAR), a cytoprotective signaling pathway. Indeed,
treatment with Halofuginone protects mice from Th17-
associated EAE [65]. Further, the cardiac glycoside Digoxin
inhibits murine Th17 cell diﬀerentiation without aﬀecting
diﬀerentiation of other T-cell lineages and reduces the se-
verity of EAE in mice [66]. In addition, leukemia inhibitory
factor (LIF) produced by neural progenitor cells is able to
ameliorateEAEbyselectivelyinhibitingpathogenicTh17cell
diﬀerentiation [67, 68].
7.Th17 CellsinHumanPathology and
FDA-ApprovedDrugs
In addition to preclinical results, clinical data show a cor-
relation between enhanced IL-17 production and increased
frequencies of Th17 cells in human disease (summarized
in Table 2). High IL-17 levels are detected in the sera and
biopsies of RA and SLE patients [18, 69–71]. Ex vivo, IL-17A
promotesinductionofproinﬂammatorycytokinesIL-1β and
IL-6 expression in synoviocytes from RA patients [72].
In MS patients, IL-17A mRNA is detected in cere-
brospinalﬂuidmononuclearcells,andmyelinreactiveTh17+
cells are also enriched [73]. Indeed, Th17+ cells from MS
patients produce high amounts of IL-22 and IFNγ and have6 International Journal of Inﬂammation
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Figure 2: Linking Th17 cells and IL-17 to infection and autoimmunity.
Table 2: Clinical aspect of therapies targeting the IL-17 pathway.
Disease Sera Biopsies Cell type SNPs or
mutations
Therapy targeting Th17
pathway
Reference
Multiple sclerosis
IL-17A mRNA is
detected in
cerebrospinal ﬂuid
mononuclear cells
Myelin-reactive
Th17+ cells are
enriched and express
high IL-22 and IFNγ
Anti-p40 subunit of IL-12/23
(ustekinumab) (no effect)
[73–75]
Rheumatoid
arthritis IL-17 ↑ IL-17 ↑
Synoviocytes express
IL-1b and IL-6 in
response to IL-17
Anti-IL-6R (Tocilizumab); IL-
1 receptor antagonist (anakin-
ra);anti-IL17(LY2439821,oth-
ers)
[69, 72, 76–78]
Systemic lupus
erythematosus IL-17 ↑ IL-17 ↑ [18, 70, 71]
Psoriasis IL-17A, IL-22, and
IL-23 ↑
CD8+ T cells secreting
IL-17 and IL-22
(Tc17 and Tc22,
respectively)
IL-23
pathway
Anti-p40 subunit of IL-12 and
IL-23 (ustekinumab)
[79–82]
Inﬂammatory
Bowel disease
IL-23
pathway
[83]
Crohn’s disease
IL-17+ (RORγT+
IL-23R+ and
CCR6+cells) ↑
Th17 (CD161+CD4+
Tc e l l s )
Anti-IL-6R (Tocilizumab); anti-
p40 subunit of IL-12/23 (us-
tekinumab)
[76, 84–86]
the ability to cross the blood brain barrier, which likely con-
tributes to the mechanism of disease pathology [74].
Moreover, CD8+ T cells secreting IL-17 and IL-22 (Tc17
and Tc22, resp.) are thought to mediate pathogenic inﬂam-
mation in psoriasis. In fact, IL-17A, IL-22, and IL-23 are
elevated in psoriatic skin, and IL-17A together with TNFα
induces the expression of genes involved in psoriasis in
human keratinocytes [79, 80]. Furthermore, single-nucleo-
tide polymorphisms (SNPs) in genes involved in IL-23 sig-
naling (IL23A, IL23R, and IL12B) are also associated with
psoriasis[87].Inaddition,uncommonIl23r variantsinverse-
ly correlated with susceptibility to IBD have also been found
in IBD patients [83].
A signiﬁcantly higher number of IL-17+ cells is detected
in disease-aﬀected gut areas compared to healthy areas of the
same subjects with Crohn’s disease (CD) [84]. These cells
express RORγT and are IL-23R+ and CCR6+. Functionally,
they are capable of providing B-cell help, display low cyto-
toxic ability, and are resistant to Foxp3+ Treg suppression.
Together this data demonstrates that Th17+ cells are indeed
detectedintheinﬂamedtissuesofCDpatients.Anadditional
marker for Th17 cells in humans could be the C-type lectin-
like receptor CD161, which has recently been described to
promote T-cell expansion and is expressed on a discrete
subset of human CD4+ T cells in circulation and in the gut of
CD patients [85]. CD161+CD4+ T cells display an activated
Th17 phenotype as indicated by increased expression of IL-
23R and production of IL-17 and IL-22.
Biologic therapeutics blocking pathways implicated in
Th17 development or blocking IL-17 itself are currently be-
ing developed. An anti-IL6 receptor antibody (tocilizumab,
Hoﬀmann-La Roche and Chugai) is currently used to treatInternational Journal of Inﬂammation 7
RA and Crohn’s disease [76], while ongoing clinical trials
are being developed by diverse biotechnology and pharma-
ceutical companies. While IL-6 signaling is important for
Th17 development, it remains unclear if the mechanism of
action of this blocking antibody is through prevention of
Th17 development.
IL-1 receptor antagonist (anakinra) has been successfully
used in treatment of RA [77] and the mechanism of action
could be mediated by reduction of Th17+ cells, although
IL-1R signaling aﬀects several immune pathways. Further
studies are required to determine if Th17 cells are aﬀected
by either of these therapies.
In addition, blockade of IL-23 signaling using a mono-
clonal antibody (ustekinumab) against the p40 subunit of
IL-12 and IL-23 has been shown to be eﬀective in Crohn’s
disease, psoriasis and psoriatic arthritis with results similar
to those seen when blocking IL-6 or TNFα [81, 82, 86]. This
antibody has no substantial eﬀect as a therapy for MS despite
several preclinical studies using the EAE model in mice
[75], providing additional evidence that ﬁndings generated
in animal studies need to be veriﬁed using human samples in
order to be validated.
A humanized antibody blocking IL-17A is being devel-
oped to treat RA (LY2439821, Eli Lilly)[78], and phase I
clinical trials showed positive results. Another humanized
anti-IL-17 antibody is being developed for the treatment of
RA,psoriasis,anduveitis[88].Patientstreatedwiththisanti-
body show a similar reduction in symptoms to those treated
with the anti-TNF blocking antibody inﬂiximab (Remi-
cade), validating IL-17A as a strong mediator in inﬂamma-
tory autoimmune diseases.
Paradoxically, recent studies suggest that IL-17 could
have a protective role in atherosclerosis [89] and that Th17
cells seem to regulate autoimmune manifestations associated
with AIRE deﬁciency. Similarly, chronic mucocutaneous
candidiasis is associated with elevated Th17 cytokines in
APECED patients, further linking the Th17 pathway with
autoimmunity [90].
8. Adult Onset Still’s Disorder and Th17
Adult onset Still’s disorder (AOSD) is an inﬂammatory auto-
immunedisordercharacterizedbyhighspikingfever,evanes-
cent rash, arthritis, hepatosplenomegaly, variable multisys-
temic involvement, and laboratory abnormalities that in-
clude neutrophilic leukocytosis and hyperferritinaemia [91,
92]. It has been shown that proinﬂammatory cytokines IL-
1β,IL-6,andIL-18areelevatedinAOSDpatients[93–96].As
describedabove,thesecytokinesareassociatedwithinducing
and maintaining Th17 function. To test if Th17 cells were
elevated in AOSD patients, Chen et al. performed intracel-
lular cytokine staining and ﬂow cytometry to assay for Th17
cells in peripheral blood. In this study, it was found that
Th17 cells are signiﬁcantly elevated in patients with active
untreated AOSD compared to healthy volunteers. Further,
the cells decrease nearly 10-fold during clinical remission
and serum levels of ferritin decrease as well [97]. The fre-
quencies of Th17 cells are similarly elevated in patients with
active SLE, which was previously shown to have increased
Th17cells[98].Furthermore,thefrequencyofTh17cellswas
positively correlated with levels of Th17-related cytokines
(IL-17, IL-1β, IL-6, IL-18, IL-21, and IL-23) and with disease
activity score based on serum ferritin levels. Interestingly,
the frequency of Th17 cells was reduced in patients after
corticosteroid (CSs) and nonsteroidal anti-inﬂammatory
drug (NSAIDs) therapy that were in remission phase. This
newstudyshowsacorrelationbetweenTh17cellsanddisease
progression; however, it remains unknown if Th17 cells are
part of the pathogenic mechanism in development of AOSD.
An additional autoimmune disease in which the Th17
pathwayhasbeenimplicatedischildhoodHenoch-Sch¨ onlein
purpura (HSP), a common childhood systemic vasculitis in
which increased frequency of peripheral Th17 cells and se-
rum IL-17 levels occur [99]. There is also evidence from
mice suggesting that Th17 cells contribute to autoimmune
myocarditis development [100–102].
9. Conclusion
Substantial progress in understanding Th17 development
and the eﬀects of IL-17 signaling in immune responses has
revealed high potential for targeting this pathway in immune
pathologies. The ability to target or redirect T-cell lineage
development can greatly ameliorate autoinﬂammation in
preclinical models. However, a better understanding of the
cytokines involved in the induction of Th17 diﬀerentiation
and the balance between Th17 versus Treg and Th1 devel-
opment during infection or autoimmunity requires further
investigation. Finally, linking relevant animal disease models
with clinical studies could improve our understanding of
how these cells contribute to disease pathogenesis.
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